EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity

Marcio Bezerra Barcellos iD, Antônio Braga iD, Raphael Alevato iD, Sully Turon iD, Gustavo Yano Callado iD, Solange Artimos iD, Sue Yazaki Sun iD, Jorge Rezende-Filho iD, Edward Araujo Júnior iD, Andreia Cristina de Melo iD, Ross S Berkowitz iD, Neil S Horowitz iD und 1 weitere

Advances in Therapy · 2026-03 · 43 (3) · 1060-1081

DOI: 10.1007/s12325-025-03482-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advances in Therapy, online erschienen am 02.02.2026. Verfasst von Marcio Bezerra Barcellos und 12 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Program in Medical Sciences, School of Medicine, Fluminense Federal University (UFF), Niterói, RJ, 24070-090, Brazil. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Gestational Trophoblastic Disease, Immunotherapy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Gestational trophoblastic neoplasia (GTN) is a highly curable malignancy arising from placental trophoblasts, yet a small subset of patients develops multidrug resistance with limited therapeutic options. The discovery of high programmed death-ligand 1 (PD-L1) expression across trophoblastic tumors has provided a compelling biological rationale for immunotherapy, particularly immune checkpoint blockade targeting the PD-1/PD-L1 axis. OBJECTIVE: To summarize current evidence on immunotherapy in GTN, integrating biological foundations, clinical experiences, and ongoing clinical trials, and to discuss future perspectives toward individualized, fertility-preserving management. METHODS: A narrative review was conducted according to structured PRISMA-based principles. Literature was retrieved from PubMed, Scopus, and Web of Science from 2000 to 2025 using predefined descriptors related to GTN and immunotherapy. Eligible studies included clinical trials, case series, case reports, and translational research addressing immune checkpoint inhibitors in GTN. RESULTS: GTN exhibits high PD-L1 expression, mirroring the immune-privileged nature of the placenta. Checkpoint inhibitors alone, such as pembrolizumab, avelumab, or the combination of camrelizumab plus apatinib (that potently suppresses the kinase activity of vascular endothelial growth factor 2), have demonstrated complete and durable responses in approximately 70-80% of patients with multidrug-resistant GTN, with acceptable safety and preserved fertility. CONCLUSIONS: Immunotherapy has expanded therapeutic GTN, transforming refractory disease as a result of its immune responsiveness. Checkpoint inhibition not only achieves high remission rates but also offers fertility preservation and long-term survivorship. The future challenge lies in optimizing combination strategies, refining biomarkers, and ensuring equitable global access to these emerging treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsGestational Trophoblastic DiseaseImmunotherapyHumansFemalePregnancyAntibodies, Monoclonal, HumanizedB7-H1 AntigenFertility Preservation

Stichwörter der Autor:innen

AvelumabCamrelizumabCheckpoint inhibitorsChoriocarcinomaFertility preservationGestational trophoblastic neoplasiaImmunotherapyPD-1PD-L1Pembrolizumab

Substanzen

Immune Checkpoint InhibitorsAntibodies, Monoclonal, HumanizedB7-H1 AntigenCD274 protein, human

Autor:innen und Institutionen

  • Postgraduate Program in Medical Sciences, School of Medicine, Fluminense Federal University (UFF), Niterói, RJ, 24070-090, Brazil.
  • Department of Gynecology and Obstetrics, School of Medicine, Maternity School, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, 22240-003, Brazil.
  • Department of General and Specialized Surgery, School of Medicine and Surgery, Federal University of the State of Rio de Janeiro (UNIRIO), Rio de Janeiro, RJ, 20270-004, Brazil.
  • Postgraduate Program in Applied Health Sciences, University of Vassouras, Vassouras, RJ, 27700-000, Brazil.
  • Albert Einstein Israelite College of Health Sciences (FICSAE), Albert Einstein Israelite Hospital, São Paulo, SP, 05652-900, Brazil.
  • Department of Obstetrics, Paulista School of Medicine, Federal University of São Paulo, São Paulo, SP, 04023-062, Brazil.

ORCID-Profile: Marcio Bezerra Barcellos, Antônio Braga, Raphael Alevato, Sully Turon, Gustavo Yano Callado, Solange Artimos, Sue Yazaki Sun, Jorge Rezende-Filho, Edward Araujo Júnior, Andreia Cristina de Melo, Ross S Berkowitz, Neil S Horowitz, Roberta Granese

Zitieren

APA

Barcellos, M. B., Braga, A., Alevato, R., Turon, S., Callado, G. Y., Artimos, S., Sun, S. Y., Rezende-Filho, J., Araujo Júnior, E., de Melo, A. C., Berkowitz, R. S., Horowitz, N. S., & Granese, R. (2026). Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity. Advances in Therapy, 43(3), 1060-1081. https://doi.org/10.1007/s12325-025-03482-3

Vancouver

Barcellos MB, Braga A, Alevato R, Turon S, Callado GY, Artimos S, et al. Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity. Advances in Therapy. 2026;43(3):1060-1081. doi:10.1007/s12325-025-03482-3

BibTeX
@article{Barcellos2026,
  author = {Barcellos, Marcio Bezerra and Braga, Antônio and Alevato, Raphael and Turon, Sully and Callado, Gustavo Yano and Artimos, Solange and Sun, Sue Yazaki and Rezende-Filho, Jorge and Araujo Júnior, Edward and de Melo, Andreia Cristina and Berkowitz, Ross S and Horowitz, Neil S and Granese, Roberta},
  title = {Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity},
  journal = {Advances in Therapy},
  year = {2026},
  volume = {43},
  number = {3},
  pages = {1060--1081},
  doi = {10.1007/s12325-025-03482-3}
}
Kostenlos starten →